Pre-made Itolizumab benchmark antibody ( Whole mAb, anti-CD6/TP120 therapeutic antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-284
Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Itolizumab (INN, trade name Alzumab) is a "first in class" humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium|
|Conditions Approved||Plaque psoriasis|
|Conditions Active||Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis|
|Conditions Discontinued||Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis|